Artificial intelligence and ultra-high performance computing methods and experiments for drug discovery: virtual screening, deep learning, molecular dynamics simulations, ADMET modelling, and experimental validation.

Recent years have witnessed considerable progress in computer-aided drug discovery, driven by the incorporation of computational technologies within both academic and pharmaceutical environments. This evolution is marked by a significant accumulation of data pertaining to detailed three-dimensional structural information, ligand properties, and their interactions with therapeutic targets. The augmentation of computational capabilities and the accessibility of extensive chemical libraries containing billions of drug-like small molecules have further facilitated this transition. To effectively utilize these resources, it is imperative to employ rapid computing methods for virtual screening, which encompass structure-driven in silico screening across vast molecular spaces, supported by efficient recurrent profiling techniques. Furthermore, advancements in deep learning methodologies are required to improve the accuracy of prediction concerning target functionalities and ligand characteristics, even when complete receptor structures are not available. Here, this review discusses the expansion of chemical space, advanced virtual screening, deep learning, molecular dynamics (MD) simulations, Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) modelling, and challenges for drug discovery. It examines how experimental validation integrates computational predictions with laboratory testing for effective candidate selection. Finally, it outlines future research directions for artificial intelligence-driven, ultra-high performance computing (UHPC) in drug discovery, offering new prospects for the economical creation of safer and more efficacious molecule-level therapies.